Temperature-Sensitive Conjugates for Platelet Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic hypothermia in clinical settings is associated with platelet activation, aggregation, and thrombotic events due to the conformational change of integrin GPIIb/IIIa, leading to bleeding complications and thrombocytopenia, and current GPIIb/IIIa blockers have significant side effects, including inhibitory effects on all circulating platelets, resulting in bleeding risks.
Innovation Solution
Development of temperature-sensitive conjugates comprising a polypeptide with repeating sequences of proline and a single-chain antibody directed against the activated form of GPIIb/IIIa, which selectively blocks the receptor only at hypothermic temperatures, preventing platelet aggregation while allowing platelet function to resume at normal body temperature.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous GPIIb/IIIa blockers are used to prevent platelet aggregation during hypothermia, then platelet function is preserved, but bleeding complications occur due to inhibition of all circulating platelets
Solution Approach 1:
The invention creates a temperature-dependent antibody with different functional properties at different temperatures. The antibody exhibits high affinity for activated GPIIb/IIIa at hypothermic temperatures (protective effect) but low affinity at normal body temperatures (avoiding harmful effects). This local quality variation resolves the contradiction by making the antibody effective only where and when needed.
Solution Approach 2:
The invention changes the temperature parameter to control antibody affinity. By designing the antibody with temperature-sensitive binding characteristics, the system achieves selective platelet inhibition at low temperatures while maintaining normal platelet function at physiological temperatures, thus preventing both thrombosis during hypothermia and bleeding complications upon rewarming.
2Reliability
If therapeutic hypothermia is applied to protect organs from ischemia, then oxygen requirements are reduced and organ protection is achieved, but platelet activation and thrombotic events occur due to GPIIb/IIIa conformational change
Solution Approach 1:
The invention applies preliminary anti-action by administering the temperature-sensitive antibody before hypothermic conditions induce platelet activation. The antibody is already present in the system to counteract the thrombotic effects when hypothermia is induced, preventing platelet aggregation and thrombus formation while allowing organ protection to occur.
Solution Approach 2:
The temperature-sensitive antibody acts as an intermediary between the hypothermic condition and the platelet GPIIb/IIIa receptor. It selectively binds to and blocks the activated receptor form at low temperatures, mediating the interaction between therapeutic hypothermia and platelet function to prevent harmful thrombotic events while preserving the beneficial organ protection effects.
3Reliability
If current GPIIb/IIIa blockers are used to inhibit platelet aggregation, then thrombotic events are prevented, but all circulating platelets are inhibited leading to bleeding risks
Solution Approach 1:
The invention introduces dynamic temperature-dependent behavior to the antibody. The antibody's binding affinity is not static but dynamically changes with temperature, being high at hypothermic temperatures to prevent thrombosis and low at normal temperatures to avoid bleeding complications. This dynamic property allows selective platelet inhibition only when thermally induced.
Solution Approach 2:
The antibody exhibits local quality variation based on temperature conditions. At hypothermic temperatures, it has high affinity for activated GPIIb/IIIa providing thrombosis protection. At normal body temperatures, it has low affinity avoiding inhibition of circulating platelets and associated bleeding risks. This spatial-temporal quality differentiation resolves the contradiction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The temperature-sensitive conjugate effectively inhibits platelet aggregation and thrombosis during hypothermia, reducing the risk of bleeding complications and preserving platelet function upon rewarming, thereby enhancing the safety of therapeutic hypothermia protocols.
Implementation Method 1
the temperature sensitive polymer is a polypeptide with repeating sequences comprising proline... the temperature sensitive peptide takes on a beta-sheet structure at a transition temperature of greater than about 28, 29, 30, 31, 32, 33, or 34 degrees Celsius
Implementation Method 2
the antibody binds specifically to the activated conformation of GPIIb/IIIa... Temperature-responsive elastin-like polypeptide linkers have been disclosed to modulate single-chain antibody affinity
Data Source
AI summary
This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.